

**TDMS No.** 93020 - 07  
**Test Type:** CHRONIC  
**Route:** SKIN APPLICATION  
**Species/Strain:** RATS/F 344

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
DIISOPROPYLCARBODIIMIDE  
**CAS Number:** 693-13-0  
**Pathologist:** HEATH, J. - DURBIN, L. - ALLISON, M.  
Final #2/Rats

**Date Report Reqsted:** 08/08/2005  
**Time Report Reqsted:** 08:54:04  
**First Dose M/F:** 04/24/00 / 04/24/00  
**Lab:** SRI

**C Number:** C93020D  
**Lock Date:** 03/14/2003  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	18	12	10	23
Natural Death	12	8	8	10
Survivors				
Terminal Sacrifice	20	30	32	17
Animals Examined Microscopically	50	50	50	50
<b>ALIMENTARY SYSTEM</b>				
Intestine Large, Cecum	(50)	(50)	(50)	(49)
Ulcer	1 (2%)			
Edema	1 (2%)	2 (4%)	4 (8%)	2 (4%)
Hemorrhage			1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(50)
Inflammation, Chronic Active		1 (2%)		
Intestine Small, Duodenum	(49)	(49)	(49)	(49)
Epithelium, Hyperplasia		1 (2%)	2 (4%)	1 (2%)
Liver	(50)	(50)	(50)	(50)
Angiectasis	2 (4%)	2 (4%)	1 (2%)	1 (2%)
Clear Cell Focus	16 (32%)	11 (22%)	14 (28%)	8 (16%)
Mixed Cell Focus	4 (8%)	6 (12%)	6 (12%)	4 (8%)
Basophilic Focus	14 (28%)	14 (28%)	22 (44%)	9 (18%)
Hepatodiaphragmatic Nodule	5 (10%)	5 (10%)	7 (14%)	8 (16%)
Eosinophilic Focus	6 (12%)	2 (4%)	7 (14%)	4 (8%)
Degeneration, Cystic	3 (6%)	5 (10%)	4 (8%)	
Necrosis, Focal		1 (2%)	1 (2%)	
Infiltration Cellular, Mixed Cell		2 (4%)	4 (8%)	
Regeneration		1 (2%)	1 (2%)	
Hemorrhage			2 (4%)	1 (2%)
Metaplasia, Atypical				1 (2%)
Cyst				1 (2%)
Bile Duct, Hyperplasia	33 (66%)	36 (72%)	31 (62%)	17 (34%)
Centrilobular, Necrosis	4 (8%)	3 (6%)	2 (4%)	
Hepatocyte, Vacuolization Cytoplasmic	6 (12%)	6 (12%)	7 (14%)	1 (2%)
Kupffer Cell, Pigmentation		2 (4%)		
Mesentery	(9)	(9)	(12)	(6)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Accessory Spleen	1 (11%)			
Fat, Necrosis	7 (78%)	6 (67%)	8 (67%)	3 (50%)
Pancreas	(50)	(50)	(50)	(50)
Atrophy	18 (36%)	28 (56%)	32 (64%)	21 (42%)
Cyst	2 (4%)	3 (6%)	5 (10%)	3 (6%)
Hemorrhage			1 (2%)	
Acinus, Cytoplasmic Alteration		1 (2%)	1 (2%)	1 (2%)
Acinus, Hyperplasia, Focal	2 (4%)	5 (10%)	4 (8%)	
Salivary Glands	(49)	(50)	(50)	(50)
Atrophy	1 (2%)		1 (2%)	2 (4%)
Necrosis			1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(49)
Inflammation, Chronic	2 (4%)	1 (2%)		2 (4%)
Ulcer	7 (14%)	6 (12%)	6 (12%)	2 (4%)
Erosion	1 (2%)	1 (2%)	1 (2%)	
Edema	3 (6%)	3 (6%)	5 (10%)	2 (4%)
Perforation	1 (2%)		1 (2%)	
Diverticulum		1 (2%)		
Epithelium, Hyperplasia	7 (14%)	6 (12%)	8 (16%)	5 (10%)
Stomach, Glandular	(50)	(50)	(50)	(49)
Inflammation, Chronic	1 (2%)	1 (2%)		
Erosion	7 (14%)	6 (12%)	3 (6%)	3 (6%)
Ulcer	4 (8%)	2 (4%)	3 (6%)	1 (2%)
Cyst		1 (2%)	1 (2%)	
Edema		2 (4%)		
Glands, Hyperplasia	2 (4%)		1 (2%)	1 (2%)
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	41 (82%)	44 (88%)	44 (88%)	36 (72%)
Thrombosis	5 (10%)	1 (2%)	5 (10%)	
Inflammation, Chronic		1 (2%)	1 (2%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(50)
Degeneration, Fatty	12 (24%)	11 (22%)	15 (30%)	8 (16%)
Hyperplasia, Diffuse	1 (2%)			
Hyperplasia, Focal	8 (16%)	8 (16%)	5 (10%)	5 (10%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Accessory Adrenal Cortical Nodule	17 (34%)	16 (33%)	16 (32%)	9 (18%)
Hypertrophy, Focal	3 (6%)	2 (4%)	7 (14%)	3 (6%)
Adrenal Medulla	(50)	(48)	(50)	(50)
Hyperplasia	7 (14%)	9 (19%)	16 (32%)	3 (6%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia	2 (4%)			
Parathyroid Gland	(49)	(48)	(49)	(48)
Hyperplasia		1 (2%)		
Hyperplasia, Focal				1 (2%)
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Angiectasis		4 (8%)	1 (2%)	2 (4%)
Pars Distalis, Cyst	2 (4%)	3 (6%)	1 (2%)	1 (2%)
Pars Distalis, Hyperplasia, Focal	3 (6%)	7 (14%)	7 (14%)	5 (10%)
Pars Intermedia, Cyst		1 (2%)	1 (2%)	1 (2%)
Thyroid Gland	(50)	(50)	(50)	(50)
Ultimobranchial Cyst	1 (2%)			2 (4%)
C-cell, Hyperplasia	8 (16%)	12 (24%)	3 (6%)	3 (6%)
Follicle, Cyst	4 (8%)	5 (10%)	2 (4%)	3 (6%)
Follicular Cell, Hyperplasia	3 (6%)		1 (2%)	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm				1 (2%)
Preputial Gland	(50)	(50)	(50)	(50)
Inflammation, Chronic	18 (36%)	26 (52%)	17 (34%)	9 (18%)
Hyperplasia	2 (4%)			1 (2%)
Cyst		2 (4%)	2 (4%)	1 (2%)
Prostate	(50)	(50)	(50)	(50)
Inflammation, Chronic	40 (80%)	32 (64%)	35 (70%)	25 (50%)
Epithelium, Hyperplasia	4 (8%)	10 (20%)	2 (4%)	3 (6%)
Testes	(50)	(50)	(50)	(50)
Germinal Epithelium, Atrophy	12 (24%)	11 (22%)	24 (48%)	14 (28%)
Interstitial Cell, Hyperplasia	6 (12%)	6 (12%)	8 (16%)	8 (16%)

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Myelofibrosis	2 (4%)	1 (2%)		
Hyperplasia	3 (6%)	7 (14%)	3 (6%)	1 (2%)
Infiltration Cellular, Histiocyte			1 (2%)	1 (2%)
Lymph Node	(18)	(14)	(16)	(13)
Mediastinal, Ectasia	3 (17%)	1 (7%)	1 (6%)	
Mediastinal, Hemorrhage	2 (11%)	1 (7%)	4 (25%)	6 (46%)
Mediastinal, Hyperplasia, Lymphoid	7 (39%)	5 (36%)	5 (31%)	7 (54%)
Mediastinal, Pigmentation	2 (11%)	3 (21%)	5 (31%)	3 (23%)
Pancreatic, Ectasia			1 (6%)	
Pancreatic, Hemorrhage	2 (11%)		2 (13%)	2 (15%)
Pancreatic, Hyperplasia, Lymphoid		1 (7%)	2 (13%)	
Pancreatic, Pigmentation	1 (6%)	1 (7%)		3 (23%)
Lymph Node, Mandibular	(0)	(1)	(4)	(1)
Ectasia			2 (50%)	
Hemorrhage				1 (100%)
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Hemorrhage	10 (20%)	3 (6%)	11 (22%)	6 (12%)
Hyperplasia, Lymphoid	18 (36%)	15 (30%)	20 (40%)	15 (30%)
Ectasia	3 (6%)	5 (10%)	3 (6%)	1 (2%)
Pigmentation	15 (30%)	8 (16%)	16 (32%)	12 (24%)
Spleen	(50)	(50)	(50)	(50)
Hematopoietic Cell Proliferation	10 (20%)	9 (18%)	11 (22%)	4 (8%)
Pigmentation	9 (18%)	5 (10%)	6 (12%)	25 (50%)
Fibrosis	2 (4%)	3 (6%)	2 (4%)	2 (4%)
Necrosis	2 (4%)	1 (2%)	1 (2%)	1 (2%)
Hemorrhage		1 (2%)		
Lymphoid Follicle, Atrophy	1 (2%)		1 (2%)	2 (4%)
Lymphoid Follicle, Hyperplasia		1 (2%)		1 (2%)
Thymus	(49)	(46)	(46)	(49)
Hemorrhage	1 (2%)			5 (10%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(49)	(48)	(47)	(48)
Hyperplasia	31 (63%)	25 (52%)	29 (62%)	10 (21%)
Skin	(49)	(50)	(50)	(50)
Inflammation, Chronic	5 (10%)	1 (2%)	2 (4%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Ulcer	4 (8%)	5 (10%)	5 (10%)	4 (8%)
Cyst Epithelial Inclusion		4 (8%)	2 (4%)	
Epidermis, Hyperplasia	9 (18%)	7 (14%)	8 (16%)	6 (12%)
Epidermis, Skin, Site Of Application, Hyperplasia	1 (2%)	10 (20%)	29 (58%)	19 (38%)
Skin, Site Of Application, Erosion			1 (2%)	
Skin, Site Of Application, Inflammation, Chronic		6 (12%)	12 (24%)	11 (22%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Cranium, Osteopetrosis				1 (2%)
Femur, Osteopetrosis	1 (2%)			
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Compression	16 (32%)	10 (20%)	15 (30%)	4 (8%)
Hydrocephalus	7 (14%)	1 (2%)	5 (10%)	2 (4%)
Hemorrhage	1 (2%)		3 (6%)	11 (22%)
Gliososis			1 (2%)	2 (4%)
Arteriole, Necrosis, Fibrinoid				5 (10%)
Neuron, Necrosis		1 (2%)		16 (32%)
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Infiltration Cellular, Histiocyte	21 (42%)	19 (38%)	21 (42%)	12 (24%)
Hemorrhage	6 (12%)	6 (12%)	7 (14%)	17 (34%)
Inflammation, Chronic	9 (18%)	13 (26%)	16 (32%)	12 (24%)
Edema	2 (4%)	2 (4%)		2 (4%)
Metaplasia, Osseous		2 (4%)	2 (4%)	1 (2%)
Alveolar Epithelium, Hyperplasia	10 (20%)	4 (8%)	6 (12%)	6 (12%)
Nose	(50)	(50)	(50)	(50)
Foreign Body	13 (26%)	22 (44%)	12 (24%)	12 (24%)
Inflammation, Chronic	15 (30%)	22 (44%)	13 (26%)	11 (22%)
Respiratory Epithelium, Hyperplasia	11 (22%)	11 (22%)	8 (16%)	9 (18%)
Respiratory Epithelium, Metaplasia,	2 (4%)			1 (2%)

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Squamous				
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Cataract		1 (2%)	2 (4%)	1 (2%)
Cornea, Hyperplasia			1 (2%)	5 (10%)
Cornea, Inflammation, Chronic		1 (2%)	5 (10%)	23 (46%)
Cornea, Ulcer				1 (2%)
Retina, Degeneration	4 (8%)	1 (2%)	6 (12%)	3 (6%)
Harderian Gland	(50)	(50)	(50)	(50)
Inflammation, Chronic		1 (2%)	1 (2%)	
Hyperplasia, Focal		1 (2%)		1 (2%)
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Nephropathy	43 (86%)	46 (92%)	42 (84%)	30 (60%)
Inflammation, Chronic	3 (6%)	5 (10%)	9 (18%)	1 (2%)
Cyst				1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet		1 (2%)		
Renal Tubule, Dilatation		1 (2%)		1 (2%)
Renal Tubule, Hyperplasia	1 (2%)			
Renal Tubule, Necrosis	2 (4%)		2 (4%)	
Renal Tubule, Pigmentation	2 (4%)	4 (8%)		
Transitional Epithelium, Hyperplasia			1 (2%)	
Urethra	(0)	(0)	(1)	(0)
Angiectasis			1 (100%)	
Urinary Bladder	(50)	(50)	(50)	(49)
Hemorrhage			1 (2%)	3 (6%)
Inflammation, Chronic			2 (4%)	4 (8%)
Transitional Epithelium, Hyperplasia			1 (2%)	

\*\*\* END OF MALE \*\*\*

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	13	9	10	14
Natural Death	7	9	8	10
Survivors				
Terminal Sacrifice	30	32	32	25
Other				1
Animals Examined Microscopically	50	50	50	49
<b>ALIMENTARY SYSTEM</b>				
Intestine Large, Cecum	(50)	(50)	(50)	(49)
Edema	1 (2%)	3 (6%)	1 (2%)	2 (4%)
Inflammation, Chronic		1 (2%)		
Intestine Large, Rectum	(50)	(48)	(43)	(44)
Hemorrhage				1 (2%)
Intestine Small, Duodenum	(49)	(50)	(50)	(49)
Epithelium, Hyperplasia	1 (2%)			
Intestine Small, Jejunum	(47)	(50)	(50)	(46)
Epithelium, Hyperplasia			1 (2%)	
Liver	(50)	(50)	(50)	(49)
Basophilic Focus	42 (84%)	43 (86%)	45 (90%)	40 (82%)
Infiltration Cellular, Mixed Cell	8 (16%)	11 (22%)	13 (26%)	8 (16%)
Mixed Cell Focus	3 (6%)	5 (10%)	7 (14%)	1 (2%)
Hematopoietic Cell Proliferation	1 (2%)		1 (2%)	
Necrosis, Focal	5 (10%)	1 (2%)	3 (6%)	4 (8%)
Eosinophilic Focus	4 (8%)	3 (6%)	8 (16%)	5 (10%)
Clear Cell Focus	10 (20%)	6 (12%)	4 (8%)	4 (8%)
Hepatodiaphragmatic Nodule	11 (22%)	6 (12%)	12 (24%)	8 (16%)
Regeneration	1 (2%)			2 (4%)
Hemorrhage		1 (2%)	2 (4%)	1 (2%)
Cyst			1 (2%)	
Angiectasis			1 (2%)	1 (2%)
Bile Duct, Hyperplasia	5 (10%)	3 (6%)	2 (4%)	5 (10%)
Centrilobular, Necrosis	1 (2%)			2 (4%)
Hepatocyte, Vacuolization Cytoplasmic	5 (10%)	5 (10%)	3 (6%)	4 (8%)
Kupffer Cell, Pigmentation	1 (2%)	1 (2%)		1 (2%)



TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Mesentery	(11)	(12)	(9)	(9)
Fat, Necrosis	11 (100%)	11 (92%)	8 (89%)	9 (100%)
Oral Mucosa	(1)	(0)	(2)	(0)
Cyst			1 (50%)	
Pancreas	(50)	(50)	(50)	(49)
Atrophy	15 (30%)	16 (32%)	18 (36%)	19 (39%)
Cyst	4 (8%)	6 (12%)	5 (10%)	
Necrosis				1 (2%)
Acinus, Cytoplasmic Alteration		1 (2%)	1 (2%)	
Acinus, Hyperplasia, Focal		1 (2%)	1 (2%)	
Salivary Glands	(50)	(50)	(50)	(48)
Atrophy	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(50)	(50)	(49)
Ulcer	3 (6%)		1 (2%)	4 (8%)
Edema	2 (4%)		1 (2%)	2 (4%)
Epithelium, Hyperplasia	4 (8%)		2 (4%)	2 (4%)
Stomach, Glandular	(50)	(50)	(50)	(49)
Erosion	1 (2%)	1 (2%)	2 (4%)	4 (8%)
Ulcer		1 (2%)	1 (2%)	1 (2%)
Edema			1 (2%)	1 (2%)
Glands, Hyperplasia	1 (2%)		1 (2%)	
CARDIOVASCULAR SYSTEM				
Heart	(50)	(50)	(50)	(49)
Cardiomyopathy	30 (60%)	39 (78%)	35 (70%)	31 (63%)
Thrombosis	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Inflammation, Chronic		1 (2%)		1 (2%)
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(49)
Degeneration, Fatty	20 (40%)	15 (30%)	16 (32%)	17 (35%)
Hyperplasia, Focal	3 (6%)		4 (8%)	5 (10%)
Hypertrophy, Focal	10 (20%)	10 (20%)	9 (18%)	8 (16%)
Accessory Adrenal Cortical Nodule	9 (18%)	6 (12%)	9 (18%)	8 (16%)
Adrenal Medulla	(49)	(50)	(50)	(49)
Hyperplasia	5 (10%)	2 (4%)	4 (8%)	2 (4%)
Islets, Pancreatic	(50)	(50)	(50)	(49)
Hyperplasia	1 (2%)		2 (4%)	

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Metaplasia, Hepatocyte		1 (2%)		
Pituitary Gland	(50)	(50)	(50)	(49)
Pars Distalis, Angiectasis	1 (2%)	6 (12%)	4 (8%)	4 (8%)
Pars Distalis, Cyst	16 (32%)	6 (12%)	15 (30%)	14 (29%)
Pars Distalis, Hyperplasia, Focal	7 (14%)	7 (14%)	10 (20%)	11 (22%)
Pars Intermedia, Angiectasis		1 (2%)	2 (4%)	2 (4%)
Pars Intermedia, Cyst	1 (2%)	1 (2%)	2 (4%)	
Thyroid Gland	(50)	(50)	(50)	(49)
Ultimobranchial Cyst				2 (4%)
C-cell, Hyperplasia	17 (34%)	14 (28%)	10 (20%)	12 (24%)
Follicle, Cyst	2 (4%)	2 (4%)	3 (6%)	1 (2%)
Follicular Cell, Hyperplasia	1 (2%)		1 (2%)	1 (2%)

#### GENERAL BODY SYSTEM

None

#### GENITAL SYSTEM

Clitoral Gland	(50)	(49)	(50)	(49)
Inflammation, Chronic	13 (26%)	2 (4%)	10 (20%)	3 (6%)
Cyst	1 (2%)	3 (6%)	1 (2%)	3 (6%)
Hyperplasia		2 (4%)	2 (4%)	
Ovary	(50)	(50)	(50)	(49)
Cyst	11 (22%)	8 (16%)	9 (18%)	6 (12%)
Angiectasis	1 (2%)			
Corpus Luteum, Hyperplasia	1 (2%)			
Uterus	(50)	(50)	(50)	(49)
Endometrium, Hyperplasia, Cystic	4 (8%)	10 (20%)	5 (10%)	9 (18%)
Vagina	(6)	(6)	(5)	(11)
Inflammation, Chronic	1 (17%)			
Cyst	1 (17%)	1 (17%)		

#### HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(49)
Hyperplasia	6 (12%)	8 (16%)	3 (6%)	6 (12%)
Myelofibrosis		1 (2%)	2 (4%)	2 (4%)
Infiltration Cellular, Histiocyte				2 (4%)

TDMS No. 93020 - 07  
Test Type: CHRONIC  
Route: SKIN APPLICATION  
Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
DIISOPROPYLCARBODIIMIDE  
CAS Number: 693-13-0  
Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
Time Report Requested: 08:54:04  
First Dose M/F: 04/24/00 / 04/24/00  
Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Lymph Node	(13)	(10)	(14)	(8)
Deep Cervical, Hemorrhage		1 (10%)		
Deep Cervical, Hyperplasia, Lymphoid		1 (10%)		
Deep Cervical, Pigmentation		1 (10%)		
Mediastinal, Ectasia			1 (7%)	
Mediastinal, Hemorrhage	4 (31%)	4 (40%)	4 (29%)	3 (38%)
Mediastinal, Hyperplasia, Lymphoid	3 (23%)	5 (50%)	7 (50%)	
Mediastinal, Pigmentation	6 (46%)	6 (60%)	9 (64%)	2 (25%)
Pancreatic, Hemorrhage	1 (8%)	3 (30%)	1 (7%)	1 (13%)
Pancreatic, Hyperplasia, Lymphoid		1 (10%)		
Pancreatic, Pigmentation	1 (8%)	2 (20%)	1 (7%)	1 (13%)
Lymph Node, Mandibular	(3)	(7)	(1)	(2)
Ectasia	1 (33%)	4 (57%)		1 (50%)
Hyperplasia, Lymphoid	1 (33%)			
Pigmentation	1 (33%)	1 (14%)		
Lymph Node, Mesenteric	(50)	(50)	(50)	(48)
Pigmentation	25 (50%)	24 (48%)	27 (54%)	17 (35%)
Hemorrhage	11 (22%)	11 (22%)	6 (12%)	5 (10%)
Hyperplasia, Lymphoid	16 (32%)	20 (40%)	12 (24%)	11 (23%)
Ectasia		1 (2%)		1 (2%)
Necrosis				1 (2%)
Spleen	(50)	(50)	(50)	(49)
Pigmentation	10 (20%)	16 (32%)	13 (26%)	16 (33%)
Hematopoietic Cell Proliferation	21 (42%)	29 (58%)	29 (58%)	20 (41%)
Necrosis	1 (2%)	1 (2%)	2 (4%)	
Fibrosis		1 (2%)		2 (4%)
Hemorrhage				2 (4%)
Hyperplasia, Reticulum Cell				1 (2%)
Lymphoid Follicle, Atrophy		2 (4%)		1 (2%)
Lymphoid Follicle, Hyperplasia	1 (2%)		3 (6%)	1 (2%)
Thymus	(50)	(48)	(49)	(46)
Hyperplasia, Lymphoid	1 (2%)	2 (4%)	1 (2%)	1 (2%)
Hemorrhage	2 (4%)	2 (4%)	1 (2%)	1 (2%)
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(48)
Hyperplasia	45 (90%)	46 (92%)	45 (90%)	41 (85%)
Skin	(50)	(50)	(50)	(49)
Inflammation, Chronic	2 (4%)	1 (2%)		

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
Cyst Epithelial Inclusion		1 (2%)		
Ulcer			1 (2%)	
Epidermis, Skin, Site Of Application, Hyperplasia	1 (2%)	5 (10%)	16 (32%)	21 (43%)
Epidermis, Hyperplasia	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Skin, Site Of Application, Inflammation, Chronic			3 (6%)	10 (20%)
MUSCULOSKELETAL SYSTEM				
None				
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(49)
Compression	14 (28%)	13 (26%)	14 (28%)	13 (27%)
Hydrocephalus	2 (4%)	8 (16%)	1 (2%)	2 (4%)
Necrosis	2 (4%)	1 (2%)	2 (4%)	
Gliosis	1 (2%)	1 (2%)	2 (4%)	
Hemorrhage	1 (2%)	8 (16%)		
Angiectasis	1 (2%)		1 (2%)	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(49)
Inflammation, Chronic	10 (20%)	22 (44%)	19 (38%)	10 (20%)
Infiltration Cellular, Histiocyte	22 (44%)	26 (52%)	30 (60%)	27 (55%)
Hemorrhage	8 (16%)	14 (28%)	9 (18%)	13 (27%)
Metaplasia, Squamous	1 (2%)		1 (2%)	
Edema	4 (8%)	4 (8%)	3 (6%)	2 (4%)
Metaplasia, Osseous			2 (4%)	1 (2%)
Emphysema			1 (2%)	
Pigmentation				1 (2%)
Alveolar Epithelium, Hyperplasia	3 (6%)	4 (8%)	10 (20%)	1 (2%)
Nose	(50)	(50)	(50)	(49)
Foreign Body	5 (10%)		2 (4%)	3 (6%)
Inflammation, Chronic	6 (12%)	1 (2%)	2 (4%)	3 (6%)
Respiratory Epithelium, Hyperplasia	4 (8%)	1 (2%)	2 (4%)	1 (2%)

TDMS No. 93020 - 07  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 DIISOPROPYLCARBODIIMIDE  
 CAS Number: 693-13-0  
 Pathologist: HEATH, J. - DURBIN, L. - ALLISON, M.

Date Report Requested: 08/08/2005  
 Time Report Requested: 08:54:04  
 First Dose M/F: 04/24/00 / 04/24/00  
 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	40 MG/KG
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(49)
Cataract	2 (4%)	5 (10%)	3 (6%)	3 (6%)
Cornea, Hyperplasia				3 (6%)
Cornea, Inflammation, Chronic	1 (2%)	1 (2%)		3 (6%)
Retina, Degeneration	4 (8%)	7 (14%)	5 (10%)	4 (8%)
Retina, Dysplasia			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(49)
Hyperplasia, Focal	1 (2%)			
Inflammation, Chronic		1 (2%)		
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(49)
Nephropathy	32 (64%)	32 (64%)	28 (56%)	21 (43%)
Inflammation, Suppurative	1 (2%)			
Cyst	1 (2%)			
Inflammation, Chronic	2 (4%)	2 (4%)	1 (2%)	
Infarct	1 (2%)		1 (2%)	
Hemorrhage				1 (2%)
Papilla, Necrosis				1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet	2 (4%)	1 (2%)		2 (4%)
Renal Tubule, Dilatation	1 (2%)		1 (2%)	1 (2%)
Renal Tubule, Necrosis	1 (2%)	2 (4%)		2 (4%)
Transitional Epithelium, Hyperplasia			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(49)
Hemorrhage			1 (2%)	

\*\*\* END OF REPORT \*\*\*